Pinteon Therapeutics

👥 8 employees💰 Last funded Jun 2015
Biotechnology Research
LinkedIn
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease. Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope which has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Pinteon Therapeutics?
Pinteon Therapeutics has 1 investors on record on gritt.io.
When did Pinteon Therapeutics last raise funding?
The most recent investment in Pinteon Therapeutics recorded on gritt.io was in June 2015.
What industry is Pinteon Therapeutics in?
Pinteon Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.